Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The risk of lung cancer recurrence is linked to hypoxemia brought on by sleep apnea.

2.

Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management.

3.

Germline Profiling May Improve Risk Stratification in t-MNs

4.

EMA Backs Breast Cancer SERD After FDA No Vote

5.

New drug combination shows particularly good results in patients with HPV-negative head and neck cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot